Interplay Between Myeloid-Derived Suppressor Cells (Mdscs) And Th17 Cells: Foe Or Friend?

Liang Wen,Ping Gong,Chao Liang,Dawei Shou,Baoqing Liu,Yiwen Chen,Changqian Bao,Li Chen,Xiaowei Liu,Tingbo Liang,Weihua Gong
DOI: https://doi.org/10.18632/oncotarget.8204
2016-01-01
Oncotarget
Abstract:Myeloid-derived suppressor cells (MDSCs) and Th17 cells were first discovered in the fields of cancer and autoimmunity, respectively. In recent years, their activities have been explored in other biological and pathological conditions, such as infective diseases and solid organ transplantation. However, the interplay between MDSCs and Th17 cells and the mechanism of their interaction remain obscure. This review summarized and analyzed the relationship between MDSCs and Th17 cells, both of which participate in tumor, autoimmune disease, infection and other conditions. In tumors, the increase in MDSCs at the tumor site is usually accompanied by the accumulation of Th17 cells. However, their relationship is inconsistent in different tumors. In arthritic mice or rheumatoid arthritis (RA) patients, an increase in MDSCs, which could ameliorate disease symptoms, causes decreased IL-17A gene expression and Th17 cells accumulation. Furthermore, we concluded that the interaction between MDSCs and Th17 cells is mainly mediated by cytokines. However, the mechanisms require further investigation. Determining the details of their interplay will provide a better understanding of immune networks and could lead to the development of immunotherapeutic strategies in the future.
What problem does this paper attempt to address?